# Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

> **NCT00886691** · PHASE2 · COMPLETED · sponsor: **GOG Foundation** · enrollment: 150 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Everolimus
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00886691
- **Lead sponsor:** GOG Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-27
- **Primary completion:** 2014-06-27
- **Final completion:** 2015-03-23
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886691, "Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00886691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*